title: [The effect of prokinetic treatment and eradication of Helicobacter pylori on gastric emptying and symptoms of functional dyspepsia].
abstract: The aim of the study was to estimate clinical symptoms and gastric emptying in functional dyspepsia (f.d.) before and after treatment.
  
  
  METHODS
  40 patients were examined. Control group consisted of 10 healthy volunteers. The severity of symptoms was estimated in 0-3 score. Gastric emptying was measured with radionuclide method. Examinations were performed prior and after treatment with famotidine (group I), cisaprid + famotidine (group II), cisaprid (group III), eradication of H.p. (group IV).
  
  
  RESULTS
  Significantly delayed gastric emptying was observed in patients with f.d. Severity of symptoms score was significantly reduced after treatment, and was: group. I 13.8-11.2, group II. 14.8-8.8, group III 13.7-6.9, group IV 13.3-9.0. Gastric emptying was improved after treatment in groups: II 64.3-45.5 and III 65.1-46.7 respectively. In groups I and IV there was a minor nonsignificant change in gastric emptying.
  
  
  CONCLUSIONS
  1. Gastric emptying is significantly delayed in patients with f.d. 2. Prokinetic therapy with cisapride results in the improvement of gastric emptying together with alleviation of clinical symptoms of f.d. 3. Antisecretory treatment with famotidine and eradication of Helicobacter pylori do not effect gastric emptying, but exerts positive clinical response.
authors.affiliation: Kliniki Gastroenterologii Akademii Medycznej w Lublinie.
authors.forename: P
authors.initials: P
authors.lastname: Radwan
authors.forename: R
authors.initials: R
authors.lastname: Grodzieński
authors.forename: J
authors.initials: J
authors.lastname: Zaorska-Rajca
authors.forename: B
authors.initials: B
authors.lastname: Skrzydło-Radomańska
authors.forename: M
authors.initials: M
authors.lastname: Słomka
authors.forename: A
authors.initials: A
authors.lastname: Wysokiński
mesh_terms: D000293:Adolescent; D000328:Adult; D020117:Cisapride / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy*; D015738:Famotidine / Q000008:administration & dosage*; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000503:physiopathology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male
chemical_list: D015738:Famotidine; D020117:Cisapride